- cafead Jun 25, 2024 at 11:22: AM
via Patients with chronic obstructive pulmonary disease may soon have a new treatment option with fewer side effects as Verona Pharma prepares for a potential approval this week.
Wednesday, the FDA is set to decide on the New Drug Application for Verona’s ensifentrine, intended to treat chronic obstructive pulmonary disease (COPD), a condition in which patients have difficulty breathing due to restricted airflow to the lungs.
article source
Wednesday, the FDA is set to decide on the New Drug Application for Verona’s ensifentrine, intended to treat chronic obstructive pulmonary disease (COPD), a condition in which patients have difficulty breathing due to restricted airflow to the lungs.
article source